Clinical Trials Logo

Pneumococcal Disease clinical trials

View clinical trials related to Pneumococcal Disease.

Filter by:

NCT ID: NCT05408429 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

Start date: June 24, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13. This study is being conducted in children who: - are between 12 to 23 months of age; - are healthy as determined by the study doctors; - have received 2 doses of Prevnar 13 during the first year in life. Participants in this study will receive either 1 dose or 2 doses of the study vaccine or 1 dose of Prevnar 13 as a shot in the muscle. During the study, participants will have to come to the study clinic to receive the vaccines and have blood sample collected. The study team will work with participants' parents or legal guardians to monitor any unwanted reactions to the vaccines. Participants are expected to take part in this study for about 1 or 3 months, for 1 dose or 2 dose schedules, respectively.

NCT ID: NCT05393037 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Start date: July 13, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

NCT ID: NCT05329259 Completed - Clinical trials for Pneumococcal Disease

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Start date: October 6, 2022
Phase: Phase 4
Study type: Interventional

- The purpose of this study is to describe the safety of the study vaccine (called 13vPnC) in people who are 18-49 years of age in India. - This study is seeking participants who are generally healthy adults ≥18 and <50 years of age, with no prior history of pneumococcal vaccination. - Participants will take part in the study for approximately one month which includes two visits to the study clinic. - Participants will receive a single dose of study vaccine (13vPnC) into the arm at visit 1 and will come to study site for a follow-up visit after about a month.

NCT ID: NCT04887948 Completed - COVID-19 Clinical Trials

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Start date: May 20, 2021
Phase: Phase 3
Study type: Interventional

Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

NCT ID: NCT04875533 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Start date: June 14, 2021
Phase: Phase 3
Study type: Interventional

A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan

NCT ID: NCT04830358 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

Start date: May 28, 2020
Phase: Phase 1
Study type: Interventional

The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.

NCT ID: NCT04642079 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age

NCT ID: NCT04633226 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

PNEU-PED-KOR
Start date: February 10, 2021
Phase: Phase 3
Study type: Interventional

The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.

NCT ID: NCT04546425 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

NCT ID: NCT04530838 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Start date: September 16, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants